Letter to the Editor: In Response to Hematology...Literally and Seriously
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
Thoughtful commentaries on several of the most meaningful hematologic breakthroughs of 2015, written by editors of The Hematologist and selected guest experts.
Dr. Moss covers updates in the management of the most common subtype of leukemia, CLL. He focuses on the value of BTK inhibition.
Dr. Coetzer looks at advances in CRISPR-Cas9 genome editing as well as critical aspects that must be addressed and optimized before the technology can be implemented in a clinical setting to treat patients.
Dr. Gotlib provides his perspective on how the groundbreaking progress in hematology achieved during 2016 has come about as well as the need to navigate the new administration to show how seriously we take hematology.
Dr. Keel reviews promising advances during 2016 in HIT prevention and treatment, while mentioning the need for further trials to confirm the safety and efficacy of existing anticoagulants.
Dr. Garcia takes a look at the best of 2016 in the field of platelet disorders and within nonmalignant hematology through a randomized trial that compared standard care to standard care plus platelet transfusion in adult patients who were taking antiplatelet drugs and experienced ICH.
Dr. Hoggatt covers novel insights in 2016 that show that HSC mitochondria may regulate hematopoiesis and predicts 2017 will shed more light on these HSC-niche interactions.
Dr. Raje, Dr. Yee and Dr. O'Donnell discuss various daratumumab combinations that have emerged as options for the treatment of multiple myeloma.
Dr. Abdel-Wahab and Dr. Taylor review the progress made during 2016 in understanding the molecular underpinnings of acute myeloid leukemia (AML) as well as in the use of precision medicine for patients with AML.
Dr. Raetz reviews changes that have emerged in 2016 in the treatment of acute lymphocytic leukemia for both children and adults.
Dr. LaCasce discusses data that emerged in 2016 for novel immunotherapy approaches in Hodgkin lymphoma and non-Hodgkin lymphoma.
March-April 2017Volume 14, Issue 2
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology